ImageneBio Financial Results
ImageneBio reported third quarter 2026 financial results, ending the period with $126.6 million in cash and marketable securities. The company highlighted the continued progress of its Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis and plans to initiate a Phase 2 study in alopecia areata by year-end 2026.
“We are advancing our trials, developing a robust data set that we believe could demonstrate olevaprubart’s disease-modifying potential and tolerability profile across inflammatory indications. Our safety database continues to grow as we progress, and we are gaining experience across biologic- and JAK-experienced patients as well as those that are naïve to advanced therapies.”
Kristin Yarema, Ph.D., chief executive officer of Imagene
“With ADAPTIVE on course for topline data in the fourth quarter of 2027 and our alopecia areata trial on track to begin by year end, we are executing with capital discipline, and we are poised to deliver data that could demonstrate the true value potential of oleva.”
Kristin Yarema, Ph.D., chief executive officer of Imagene